Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- 05 Jul 2017 Status changed from active, no longer recruiting to recruiting.
- 19 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.